Market Cap
$227.9B
AMGN
AMGEN INC
$402.81 ▼ -1.10%
Prev close $407.27Market cap$227.9B
ConsensusHold
12-mo target$390.94 (-2.9%)
▲ Neutral
Analyst conviction 5/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)37 New Institutional Positions13 Institutional ExitsCongressional Activity (3) Biotech & Drug Discovery
Snapshot
The big-picture read on AMGN right now — valuation, ownership and activity at a glance.
Cap Size
Mega Cap
Analyst Consensus
Hold (47%)
Inst. Holders
50 funds
Inst. Value
$123.9B
Inst. Activity
37 buys / 13 sells
Insider Activity
$0.00 buy / $4.1M sell
Insider Net $
-$4.1M
SEC Reports
16
Congressional
10 trades
Price chart 30d -9.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 short_volume
Sep 10, 2026 SEC Short Volume: AMGN — 71.8% short (0.5M / 0.8M)
Short: 547,323 | Exempt: 40 | TRF Vol: 762,458 | Short Ratio: 71.8% | Off-exchange volume (dark pool
HSBC downgrades AMGN to Hold — PT $425 (-4.5%)
ANALYST-DOWNGRADE — Impact 4/10
BMO Capital double downgrade: Outperform → Market Perform
ANALYST-DOWNGRADE — Impact 4/10
Aug 26, 2026 Congress
David Taylor sell
$1,001 - $15,000 — House
Aug 26, 2026 Congress
David Taylor sell
$1,001 - $15,000 — House
Aug 21, 2026 Event
FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufactu
Aug 13, 2026 Insider
Khosla Rachna acquired via exercise 1,252 shares
SVP, Business Development @ $162.60 ($203.6K)
Aug 13, 2026 Insider
Khosla Rachna sold 1,252 shares
SVP, Business Development @ $416.43 ($521.4K)
Analyst ratings buy % -11.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
47% rate it Buy or better · 43 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 29, 2026 | Scotiabank | MAINTAIN | Sector Outperform | 56% |
| Sep 10, 2026 | HSBC | DOWNGRADE | Hold | 55% |
| Sep 8, 2026 | BMO Capital | DOWNGRADE | Market Perform | 53% |
| Sep 8, 2026 | Cantor Fitzgerald | REITERATE | Neutral | 49% |
| Sep 4, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Aug 20, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Aug 19, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
| Aug 19, 2026 | Argus Research | MAINTAIN | Buy | 54% |
| Aug 18, 2026 | Mizuho | MAINTAIN | Neutral | 52% |
| Aug 18, 2026 | Cantor Fitzgerald | MAINTAIN | Neutral | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 14 | 20 | 2 | 1 | 47% | |
| Aug 1, 2026 | 6 | 15 | 19 | 2 | 1 | 49% | |
| Jul 1, 2026 | 6 | 15 | 19 | 2 | 1 | 49% | |
| Jun 1, 2026 | 6 | 16 | 19 | 2 | 1 | 50% | |
| May 1, 2026 | 6 | 15 | 20 | 2 | 1 | 48% | |
| Apr 1, 2026 | 6 | 15 | 19 | 2 | 1 | 49% | |
| Mar 1, 2026 | 6 | 15 | 18 | 2 | 1 | 50% | |
| Feb 1, 2026 | 6 | 16 | 16 | 2 | 1 | 54% |
Price targets
Where 29 covering analysts think AMGN trades over the next 12 months.
$390.94 -2.9% upside Hold
Current$402.81 Low$225.00 Median$400.00 High$500.00 29 analysts
$225.00$500.00
Analyst rating Hold· 2.6/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 2 bullish, 4 bearish, 0 mixed, 10 neutral · avg impact 3.3/10.
NEUTRALANALYST-UPGRADE1/10
Canaccord Genuity initiates AMGN at Hold with $366 PT — 4.5% upside, ahead of earnings
Apr 21, 2026
BEARISHANALYST-DOWNGRADE4/10
HSBC downgrades AMGN to Hold — PT $425 (-4.5%)
Sep 10, 2026
BEARISHANALYST-DOWNGRADE4/10
BMO Capital double downgrade: Outperform → Market Perform
Sep 8, 2026
BULLISHCOURT-RULING7/10
Amgen and other drug manufacturers won summary judgment in D.D.C. against HHS, invalidating HRSA's c
Aug 15, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
Clinical Trial
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
Phase Phase 3 — COMPLETED
Sep 29, 2026
Clinical Trial
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
Phase Phase 2 — COMPLETED
Sep 29, 2026
short_volume
Short Volume: AMGN — 71.8% short (0.5M / 0.8M)
Short: 547,323 | Exempt: 40 | TRF Vol: 762,458 | Short Ratio: 71.8% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
Clinical Trial
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
Phase Phase 3 — COMPLETED
Sep 28, 2026
short_volume
Short Volume: AMGN — 59.3% short (0.5M / 0.8M)
Short: 460,708 | Exempt: 0 | TRF Vol: 776,314 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $5.78 | $5.48–$6.16 | 2.5% | +0.0% | 13↑ 10↓ | $10.0B | 27 |
| Next Q | $5.80 | $5.19–$6.29 | 9.7% | +0.0% | 11↑ 12↓ | $10.3B | 27 |
| Current FY | $23.06 | $22.47–$23.90 | 5.6% | +0.1% | 31↑ 1↓ | $38.9B | 33 |
| Next FY | $24.45 | $22.57–$26.33 | 6.0% | +0.2% | 31↑ 0↓ | $40.3B | 33 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $5.781 | — |
| 7d ago | $5.781 | — |
| 30d ago | $5.781 | — |
| 60d ago | $5.760 | +0.021 |
| 90d ago | $5.757 | +0.024 |
Institutional ownership
Which big funds own AMGN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $123.9B total value (342,143,900 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 37 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 49,362,016 | $17.9B | 14.4% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 35,250,101 | $12.8B | 10.3% | — |
| STATE STREET CORP | 30,560,537 | $11.1B | 8.9% | — |
| Capital World Investors | 29,075,329 | $10.5B | 8.5% | — |
| Invesco Ltd. | 16,320,446 | $5.9B | 4.8% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 15,696,068 | $5.7B | 4.6% | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 15,034,038 | $5.4B | 4.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 14,853,366 | $5.4B | 4.3% | — |
| MORGAN STANLEY | 13,653,692 | $4.9B | 4.0% | — |
| WELLS FARGO & COMPANY/MN | 7,235,462 | $2.6B | 2.1% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 5,625,584 | — | $2.0B |
| JPMORGAN CHASE & CO | TRIM | 7,277,837 | 3,588,484 | -50.7% | $1.3B |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 228,017 | 2,742,271 | +1102.7% | $993.0M |
| Capital International Investors | NEAR_EXIT | 7,122,275 | 1,668,778 | -76.6% | $604.0M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | 651,459 | 1,321,585 | +102.9% | $478.6M |
| D. E. Shaw & Co., Inc. | DOUBLED | 178,009 | 1,290,217 | +624.8% | $467.2M |
| FIRST TRUST ADVISORS LP | ADD | 640,120 | 1,131,395 | +76.7% | $409.7M |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 689,490 | 963,209 | +39.7% | $348.8M |
| CITADEL ADVISORS LLC | DOUBLED | 184,963 | 703,984 | +280.6% | $254.9M |
| Allianz Asset Management GmbH | ADD | 393,880 | 632,025 | +60.5% | $228.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
22 insiders, 50 transactions. Net -$4.1M — $0.00 bought, $4.1M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Khosla Rachna | SVP, Business Development | EXERCISE | 1,252 | $162.60 | $203.6K |
| Aug 13, 2026 | Khosla Rachna | SVP, Business Development | SELL | 1,252 | $416.43 | $521.4K |
| Aug 11, 2026 | Khosla Rachna | SVP, Business Development | SELL | 2,000 | $412.57 | $825.1K |
| Aug 7, 2026 | ISHRAK OMAR | Director | AWARD | 85.169 | — | — |
| Aug 7, 2026 | Drake Michael V | Director | AWARD | 63.876 | — | — |
| Aug 7, 2026 | HOLLEY CHARLES M | Director | AWARD | 103.419 | — | — |
| Aug 7, 2026 | Busch Matthew C. | VP, Finance & CAO | AWARD | 730 | — | — |
| Aug 6, 2026 | Miller Derek | SVP, Human Resources | EXERCISE | 2,069 | $162.60 | $336.4K |
| Aug 6, 2026 | Grygiel Nancy A. | SVP & CCO | SELL | 1,970 | $402.16 | $792.3K |
| Aug 6, 2026 | Grygiel Nancy A. | SVP & CCO | EXERCISE | 1,970 | $177.46 | $349.6K |
Congressional trades
AMGN trades disclosed by members of Congress, with disclosure delay.
5 members · 2 buys / 8 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | David Taylor | R | HOUSE | SELL | $1,001 - $15,000 | Amgen Inc | Sep 7, 2026(13d) |
| Aug 26, 2026 | David Taylor | R | HOUSE | SELL | $1,001 - $15,000 | Amgen Inc | Sep 7, 2026(13d) |
| Aug 12, 2026 | Sheldon Whitehouse | D | SENATE | SELL | $1,001 - $15,000 | Amgen Inc | Sep 2, 2026(22d) |
| Jun 2, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Amgen Inc | Jul 8, 2026(37d) |
| Apr 17, 2026 | Maria Elvira Salazar | R | HOUSE | SELL | $15,001 - $50,000 | Amgen Inc | May 11, 2026(25d) |
| Apr 7, 2026 | Mark Warner | D | SENATE | SELL | $1,001 - $15,000 | Amgen Inc | May 1, 2026(25d) |
| Apr 7, 2026 | Mark Warner | D | SENATE | SELL | $1,001 - $15,000 | Amgen Inc | May 1, 2026(25d) |
| Apr 6, 2026 | Mark Warner | D | SENATE | SELL | $1,001 - $15,000 | Amgen Inc | May 1, 2026(26d) |
| Mar 24, 2026 | Maria Elvira Salazar | R | HOUSE | BUY | $15,001 - $50,000 | Amgen Inc | Apr 22, 2026(30d) |
| Feb 26, 2026 | David Taylor | R | HOUSE | SELL | $1,001 - $15,000 | Amgen Inc | Mar 9, 2026(12d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for AMGN.
Shares short
14,063,517
Settlement Sep 15, 2026
Change vs prior
+8.4%
Semi-monthly cycle
Days to cover
4.9
At avg daily volume
Of shares outstanding
≈2.6%
Estimate — not % of float
All AMGN filing & press-release reports (16)
- Canaccord Genuity initiates AMGN at Hold with $366 PT — 4.5% upside, ahead of earningsApr 21, 2026
- HSBC downgrades AMGN to Hold — PT $425 (-4.5%)Sep 10, 2026
- BMO Capital double downgrade: Outperform → Market PerformSep 8, 2026
- COURT-RULING reportAug 15, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 13, 2026
- COURT-RULING reportAug 12, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportAug 7, 2026
- GOVT-CONTRACT reportAug 6, 2026
- 8-K reportJul 31, 2026
- COURT-RULING reportJul 8, 2026
- COURT-RULING reportJun 4, 2026
- 8-K reportMay 19, 2026
- 8-K reportApr 22, 2026
- DEFA14A reportApr 7, 2026